Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemia
| Autor: | P.M. Steiner, Charles J. Glueck, Deborah Scheel, Starr Ford |
|---|---|
| Rok vydání: | 1972 |
| Předmět: |
Male
medicine.medical_specialty Blood Protein Disorders Time Factors Diet therapy Lipoproteins Saturated fat Cholestyramine Resin Hyperlipidemias Placebo Bile Acids and Salts Placebos chemistry.chemical_compound Ethers Cyclic Internal medicine Colestipol Hydrochloride Polyamines medicine Humans Triglycerides Analysis of Variance Clinical Trials as Topic Cholestyramine business.industry Cholesterol Colestipol General Medicine Crossover study Endocrinology chemistry Female lipids (amino acids peptides and proteins) Ion Exchange Resins business Diet Therapy medicine.drug |
| Zdroj: | JAMA: The Journal of the American Medical Association. 222:676-681 |
| ISSN: | 1538-3598 0098-7484 |
| Popis: | Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipoproteinemia. Plasma cholesterol and β-lipoprotein cholesterol were reduced to normal levels in 20 and 22 subjects, respectively, by one or both drugs. Coupled with low cholesterol, low saturated fat, polyunsaturate-rich diet, colestipol and cholestyramine provide parallel and alternative approaches to normalization of cholesterol and β-lipoprotein cholesterol in familial type II hyperlipoproteinemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|